Lung Cancer Trial, Recruiting NCT05281237 Sponsor: Beth Israel Deaconess Medical Center Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05281237
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with Stage I or Stage II primary lung cancer, with a single nodule (small growth) up to 3 cm in size, confirmed by a previous tissue or cell sample
  • People whose nodule or tumour type and whether it is cancerous has been confirmed through a tissue or cell sample that meets the testing laboratory's standards
  • People whose nodule or tumour can be reached using a guided camera tube (navigational bronchoscopy) and whose nodule location can be confirmed during the procedure using a specialised type of X-ray imaging
  • People who have been assessed as suitable for surgery to remove part or all of a lung (lobectomy or a larger operation)
  • People who are at least 22 years old and are able to give their own consent to participate

Who may not be able to join:

  • People for whom a flexible camera tube procedure through the airways (flexible bronchoscopy) is considered medically unsafe
  • People whose target nodule is smaller than 1.0 cm
  • People who have previously had radiation therapy or chemotherapy directed at the target nodule or tumour
  • People with other health conditions that the trial doctor believes could affect their safety or the results of the study
  • People who have a pacemaker, an implantable heart device, or any other electronic implanted device
  • People who are unable to tolerate the bronchoscopy procedure
  • People with a blood clotting disorder
  • People who are currently participating in another therapeutic lung cancer study
  • People who are pregnant or breastfeeding
  • People who test positive for COVID-19 at the time of the procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jason Beattie, MD, Beth Israel Deaconess Medical Center

Phone: (617) 632- 8252

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
30 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of Planned Ablations.; Pathological changes in the tumor tissue.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov